Denali director granted RSUs and stock options

Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Denali Therapeutics director Peter S. Klein reported equity awards consisting of restricted stock units and stock options. He received 6,408 shares of Common Stock in the form of RSUs, with all RSUs scheduled to vest in full on the earlier of the one-year anniversary of the grant date or the day before the company’s next annual stockholder meeting after the grant date.

He was also granted a stock option covering 19,226 shares of Common Stock at an exercise price of $19.66 per share, with the option vesting on the same schedule as the RSUs. Following these awards, Klein directly owns 33,941 shares of Common Stock and holds the newly granted option for 19,226 underlying shares.

Insider Trade Summary

Grant/Award: 25,634 shares

Grant/Award 2 txns

Insider Klein Peter S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	19,226	$0.00	$0.00
Grant/Award	Common Stock	6,408	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 19,226 contracts (Direct); Common Stock — 33,941 shares (Direct)

Footnotes (3)

F1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2. Includes 6,408 unvested RSUs.
F3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Key Figures

RSU grant: 6,408 shares Option grant size: 19,226 shares Option exercise price: $19.66 per share +3 more

6 metrics

RSU grant 6,408 shares Restricted Stock Units granted to director on June 3, 2026

Option grant size 19,226 shares Stock option covering common shares granted June 3, 2026

Option exercise price $19.66 per share Exercise price for 19,226-share stock option award

Shares held after grant 33,941 shares Total direct common stock holdings following RSU grant

Underlying option shares 19,226 shares Common shares underlying the new stock option

Option expiration date June 3, 2036 Expiration of stock option if not exercised

Key Terms

Restricted Stock Unit, RSU, Stock Option (right to buy), exercise price, +1 more

5 terms

Restricted Stock Unit financial

"Each share is represented by a Restricted Stock Unit ("RSU")"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Includes 6,408 unvested RSUs."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Stock Option (right to buy) financial

"Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "19.6600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders occurring after the grant date."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Denali Therapeutics (DNLI) director Peter S. Klein receive in this Form 4?

Peter S. Klein received equity compensation in the form of 6,408 restricted stock units and a stock option for 19,226 shares. Both awards reflect non-cash grants, increasing his direct equity exposure to Denali Therapeutics through stock-based compensation rather than open-market purchases.

How many Denali Therapeutics (DNLI) RSUs were granted to Peter S. Klein?

He was granted 6,408 RSUs, each representing a right to receive one share of Denali Therapeutics common stock. These units are unvested initially and form part of his overall share ownership, aligning his incentives with long-term company performance upon vesting.

What are the vesting terms for Peter S. Klein’s RSUs at Denali Therapeutics (DNLI)?

All 6,408 RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or the day before Denali Therapeutics’ next annual stockholder meeting. This single cliff vesting schedule ties the award to the director’s upcoming service period.

What stock option grant did Peter S. Klein receive from Denali Therapeutics (DNLI)?

He received a stock option covering 19,226 shares of Denali Therapeutics common stock at an exercise price of $19.66 per share. The option provides the right, but not obligation, to buy shares at that price if it becomes economically attractive.

When do Peter S. Klein’s Denali Therapeutics (DNLI) stock options vest and expire?

One hundred percent of the option shares vest on the earlier of the one-year anniversary of the grant date or the day before the next annual stockholder meeting. The option is scheduled to expire on June 3, 2036, if not exercised earlier according to its terms.

How many Denali Therapeutics (DNLI) shares does Peter S. Klein hold after these grants?

After the RSU grant, Peter S. Klein directly holds 33,941 shares of Denali Therapeutics common stock. This total includes 6,408 unvested RSUs that will convert into shares upon vesting according to the specified one-year or next-meeting-based vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/05/2026 - 04:45 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Peter S

(Last)

(First)

(Middle)

C/O DENALI THERAPEUTICS INC.

161 OYSTER POINT BLVD.

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Denali Therapeutics Inc. [ DNLI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		A		6,408⁽¹⁾	A	$0	33,941⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$19.66	06/03/2026		A		19,226		⁽³⁾	06/03/2036	Common Stock	19,226	$0	19,226	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

2. Includes 6,408 unvested RSUs.

3. 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.

Remarks:

	/s/ Tyler Nielsen, by power of attorney	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR